NSE: FDC · BSE: 531599 · ISIN INE258B01022
FDC Limited stock analysis
FDC Limited ranks #2530 in the TickerSutra evidence-ranked universe with a score of 46/100 and 95% data confidence. The latest captured fundamentals show ROCE of 15.3%, quarterly sales growth of 3.0% and quarterly profit growth of 9.2%.Avoid / exit review
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.01×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹1,525cr | ₹254cr | ₹216cr | 17.0% |
| 2023 | ₹1,784cr | ₹251cr | ₹194cr | 14.0% |
| 2024 | ₹1,943cr | ₹339cr | ₹305cr | 17.0% |
| 2025 | ₹2,108cr | ₹325cr | ₹267cr | 15.0% |
| 2026 | ₹2,171cr | ₹346cr | ₹281cr | 16.0% |
| TTM | ₹2,190cr | ₹335cr | ₹293cr | 15.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Disclosure of Voting results of the 86th Annual general Meeting held on 24th September, 2026 along with the Scrutinizer''s Report.
RoutineFDC Ltd - 531599 - Closure of Trading WindowBSE · 25 Sept 2026Trading window of the Company shall remain closed for all the Designated Persons and their relatives with effect from 1st October , 2026, till 48 hours after the declaration of Unaudited ....
RoutineFDC Ltd - 531599 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · 18 Sept 2026Newspaper Publication - Corrigendum to 86th AGM Notice- Cut-off date & Book Closure period FY 2025-26.
RoutineCopy of Newspaper PublicationNSE · 18 Sept 2026Newspaper Publication Corrigendum to 86th AGM Notice Cut-off Date & Book Closure Period FY 2025-26
MANAGEMENT COMMENTARY
Signals from filed documents
Internationally, we expanded our presence across strategic markets by strengthening customer partnerships, broadening product registrations and maintaining an unwavering focus on quality and regulatory excellence. Enhanced supply chain resilience and operational efficiencies further supported renewed momentum in the United States, while our business in South Africa continued to perform strongly, reflecting the increa
Our Portfolio continued to make steady progress, supported by increasing market penetration, focused brand-building initiatives and a consistent emphasis on meeting evolving healthcare needs. Internationally, we expanded our presence across strategic markets by strengthening customer partnerships, broadening product registrations and maintaining an unwavering focus on quality and regulatory excellence. Enhanced suppl
Acceptability New business models are expected to strengthen penetration into Tier-2 and Tier-3 cities, expanding healthcare and pharmaceutical access across emerging markets. In FY26, India’s private hospitals are expected to add more than 4,000 beds with an estimated investment of H 11,500 crore (US$ 1.34 billion), continuing the strong capacity expansion momentum seen in the previous fiscal year. India’s generic m
Our Portfolio continued to make steady progress, supported by increasing market penetration, focused brand-building initiatives and a consistent emphasis on meeting evolving healthcare needs. Internationally, we expanded our presence across strategic markets by strengthening customer partnerships, broadening product registrations and maintaining an unwavering focus on quality and regulatory excellence. Enhanced suppl
There is a constant thrust to address patient needs and efforts to develop products for their treatment. The team has successfully developed and transferred challenging, technology intensive complex products from the laboratory to the commercial level. R&D team is very competent with members having high academic credentials such as PhD and Mpharm and having research experience of 20 + years from different pharma comp
Regulatory Filings and Pipeline During the year under review, your Company successfully completed 2 product filings in Mexico, a market that represents a significant opportunity for your Company's pharmaceutical portfolio. The Company has applied for regulatory approvals for these products and, subject to receipt of such approvals from the relevant Mexican authorities, your Company will commence commercial sales in M
UK Market FDC International Limited (" FDCIL"), your Company's wholly owned subsidiary incorporated in the United Kingdom, continued to maintain its market presence during the year under review, achieving sales of H 1,882.83 lakhs. The UK market operated in a challenging environment characterised by intensified competitive pricing pressures and delayed batch releases, which resulted in a marginal dip in sales as comp
This centre has developed and demonstrated expertise in synthetic organic chemistry, process scale up and technical capabilities of multistep organic synthesis, supported by Analytical Development using various hyphenated instruments like HPLC, Preparative HPLC,Flash chromatography, GC, UPLC,TGA,LCMS, GCMS and XRD. The work initiatives on life cycle management of existing drug substances focuses on cost effectiveness
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…